Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price lifted by KeyCorp from $12.00 to $15.00 in a research report report published on Thursday morning, FlyOnTheWall reports.
A number of other brokerages also recently commented on RXRX. Needham & Company LLC assumed coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, March 16th. They set a buy rating and a $17.00 price objective for the company. Morgan Stanley initiated coverage on Recursion Pharmaceuticals in a research report on Monday, May 22nd. They set an equal weight rating and a $8.00 target price on the stock. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals has an average rating of Hold and a consensus price target of $11.40.
Recursion Pharmaceuticals Trading Up 2.9 %
Shares of NASDAQ RXRX opened at $12.44 on Thursday. The stock has a 50 day moving average of $7.86 and a two-hundred day moving average of $7.54. The stock has a market cap of $2.39 billion, a P/E ratio of -9.01 and a beta of -0.49. Recursion Pharmaceuticals has a twelve month low of $4.54 and a twelve month high of $14.99.
Insider Activity at Recursion Pharmaceuticals
In related news, insider Shafique Virani sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $8.58, for a total value of $214,500.00. Following the sale, the insider now directly owns 161,819 shares in the company, valued at approximately $1,388,407.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Shafique Virani sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $8.58, for a total transaction of $214,500.00. Following the completion of the sale, the insider now owns 161,819 shares in the company, valued at approximately $1,388,407.02. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Christopher Gibson sold 33,073 shares of the firm’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $4.71, for a total value of $155,773.83. Following the sale, the chief executive officer now owns 953,225 shares in the company, valued at approximately $4,489,689.75. The disclosure for this sale can be found here. Insiders sold 205,419 shares of company stock valued at $1,635,060 in the last ninety days. Corporate insiders own 19.96% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of RXRX. Alpine Global Management LLC acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth approximately $120,000. Cypress Point Wealth Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 40.0% during the 4th quarter. Cypress Point Wealth Management LLC now owns 14,219 shares of the company’s stock worth $110,000 after buying an additional 4,063 shares during the last quarter. Schroder Investment Management Group raised its position in shares of Recursion Pharmaceuticals by 47.0% in the 4th quarter. Schroder Investment Management Group now owns 159,964 shares of the company’s stock worth $1,233,000 after buying an additional 51,119 shares during the period. Kinnevik AB publ acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at $59,005,000. Finally, Artal Group S.A. grew its position in Recursion Pharmaceuticals by 113.4% during the fourth quarter. Artal Group S.A. now owns 960,204 shares of the company’s stock valued at $7,403,000 after acquiring an additional 510,204 shares during the period. 64.79% of the stock is currently owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.
Recommended Stories
- Five stocks we like better than Recursion Pharmaceuticals
- Delta Takes Flight: Double-Digit Upside In Sight
- Generac Powers Up as Summer Temperatures Rise
- 3 Reasons Why Rivian Can Continue To Surge Higher
- Despite Breaking Higher, Analysts Remain Cautious HP Inc.
- PepsiCo Can Soar To New Highs In The 2nd Half
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
